Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis

Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Detaylı Bibliyografya
Yazar: Shawn, Ibna Hasan
Diğer Yazarlar: Jamiruddin, Mohd. Raeed
Materyal Türü: Tez
Dil:English
Baskı/Yayın Bilgisi: Brac University 2024
Konular:
RCC
Demographic analysis
Pazopanib
Nivolumab plus Ipilimumab
Progression-free survival
Serious adverse events
Overall adverse events
Kidneys > Cancer > Molecular aspects.
Renal cell carcinoma.
Online Erişim:http://hdl.handle.net/10361/23931

Internet

http://hdl.handle.net/10361/23931

Benzer Materyaller